Company intelligence / Profile preview

Satori Labs

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Satori is a biotechnology company focused on developing small molecule therapeutics that enhance autophagy to treat neurodegenerative diseases. By targeting the body's natural cellular "recycling" process, the company aims to clear toxic protein aggregates associated with conditions like Alzheimer's and Parkinson's. The company's platform identifies novel chemical entities that can cross the blood-brain barrier and selectively activate autophagy pathways. Satori was founded by experts in longevity and neurodegeneration and is backed by specialized life science investors.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Satori Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Satori Labs.

Explore the full profile